A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Scribed by Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John Daniel Hainsworth; Stefan Madajewicz; Thomas Michael Cosgriff; Kristen Pierce; Huiping Xu; Katherine Liau; Diane Healey

• Publisher: Springer
• Year: 2006
• Tongue: English
• Weight: 387 KB
• Volume: 60
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-006-0352-0